Sporadic amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that affects particularly motoneurons. Several pieces of evidence suggested the involvement of autoimmune mechanisms mediated by antibodies in ALS. However, the significance of those antibodies in the disease and the underlying mechanisms are unknown. Here we showed that IgG purified from a group of sporadic ALS patients, but not familial ALS patients, specifically interact with the presynaptic membrane of motoneurons through an antigen-antibody interaction and modulated synaptic transmission. Immunoreactivity against nerve terminals showed strong correlation with synaptic modulation ability. In addition, several controls have ruled out the possibility for this synaptic modulation to be mediated through proteases or nonspecific effects. Effective IgG potentiated both spontaneous and asynchronous transmitter release. Application of pharmacological inhibitors suggested that activation of this increased release required a nonconstitutive Ca 2ϩ influx through N-type (Ca v 2.2) channels and phospholipase C activity and that activation of IP 3 and ryanodine receptors were necessary to both activate and sustain the increased release. Consistent with the notion that ALS is heterogeneous disorder, our results reveal that, in ϳ50% of ALS patients, motor nerve terminals constitutes a target for autoimmune response.
Introduction
Sporadic amyotrophic lateral sclerosis (ALS) is the most common adult-onset motoneuron degenerative disease, with an invariably fatal prognosis. A variety of mechanisms have been suggested to explain ALS pathogenesis (Cleveland and Rothstein, 2001; Strong, 2003) , and several lines of evidence support the involvement of autoimmune mechanisms. T-cell infiltration at the spinal cord (Troost et al., 1990) and degenerative structural alterations associated with intracellular Ca 2ϩ ([Ca 2ϩ ] i ) increment in motor nerve terminals have been observed in ALS patients (Siklos et al., 1996) . Also, autoantibodies against ganglioside GM1, neurofilament proteins, tumor necrosis factor receptor member FAS (CD95), and voltage-dependent calcium channels (VDCCs) (Smith et al., 1992; Drachman, 2000) have been reported. Interestingly, some of this evidence correlates with observations made in research animals. In rodents treated with IgG from ALS patients (ALS-IgG), a [Ca 2ϩ ] i increment associated with degenerative structural alterations in motoneurons and synaptic plasticity at neuromuscular transmission was also observed (Engelhardt et al., 1995; Fratantoni et al., 2000; Pullen and Humphreys, 2000; Pullen et al., 2004) . ALS-IgG from ϳ50% of ALS patients trigger synaptic potentiation in spontaneous neuromuscular transmission, together with [Ca 2ϩ ] i increment (ex vivo), and can induce long-term neuromuscular dysfunction in vivo (Uchitel et al., 1988 (Uchitel et al., , 1992 Engelhardt et al., 1995; O'Shaughnessy et al., 1998; Mohamed et al., 2002) . These findings suggest that ALS-IgG may be involved in ALS pathogenesis. However, the presence and significance of these autoantibodies are still under discussion (Drachman, 2000) . Also, therapeutic immunosuppression has been ineffective, but, in all cases, the disease was exceedingly advanced (S. A. . Thus, we focused our investigations on the earliest functional alterations of the disease. We thought that ALS-IgG-mediated synaptic potentiation (ALS-IgG-sp) is the consequence of an increase in [Ca 2ϩ ] i of the motor nerve terminal (MNT) (Engelhardt et al., 1997) . Consequently, deregulation of [Ca 2ϩ ] i may lead to mitochondrial dysfunction, intracellular free radical damage, and cell death (Guegan et al., 2001; Strong, 2003) . Therefore, ALS-IgG-sp may be an early step of motoneuron degeneration in ALS. However, the significance of ALS-IgG in the alterations reported is still unclear because of opposite results by different research groups (cf. Smith et al., 1992; Arsac et al., 1996) and because of a report that showed proteolytic activity in IgG fractions from sera of ALS patients (Nyormoi, 1996) . A key issue is, therefore, to rule out that ALS-IgG-sp is produced by contaminants.
Although neuronal death could be mediated by ALS-IgG, the mechanisms underlying ALS-IgG-sp have not yet been identified. An understanding of ALS-IgG mechanism would provide useful insight not only into the relevance of autoimmune mechanisms in ALS pathogenesis but also into the prevention of motoneuronspecific cell degeneration. To address these questions, we investigated the significance of ALS-IgG in synaptic modulation, the localization of their antigenic target, and the signaling mechanisms underlying ALS-IgG-sp.
Materials and Methods

Healthy controls and ALS patients
Sera were obtained from 13 sporadic ALS patients (age, 42-68 years; eight males and five females) and 15 control patients (age, 41-70 years; eight males and seven females). We used antibodies from two types of control patients: healthy control (h-Ctrl-IgG) (n ϭ 6) and disease control (d-Ctrl-IgG) (n ϭ 9). Individual antibodies are identified with numbers from 1 to 13 (for ALS), capitals letters from A to F (for healthy controls), and lowercase letters from a to i (for disease controls). Disease control patients had been diagnosed as familial ALS (fALS) (n ϭ 3; a, b, and c), Alzheimer's disease (n ϭ 1; d), myasthenic syndrome (n ϭ 2; e and f), peripheral neuropathy (n ϭ 2; g and h), and Charcot-Marie-Tooth disease (n ϭ 1; i). The h-Ctrl-IgG and d-Ctrl-IgG jointly will be named Ctrl-IgG. ALS patients had been diagnosed as definite ALS according to the El Escorial criteria (1994) .
IgG purification
Proteins from sera were precipitated by ammonium sulfate and dialyzed against 20 mM phosphate buffer. IgG were purified by affinity chromatography using a HiTrap protein G HP column (Amersham Bioscience, Piscataway, NJ) according to the recommendations of the supplier. IgG were dialyzed against 10 mM PBS using a 12 kDa pore membrane (Millipore, Bedford, MA) membrane filtration on a 2 m filter (Millipore), and addition of BSA was performed before storage in small volumes at Ϫ20°C. Several fractions of each IgG were used to estimate IgG concentration, using a spectrophotometer reading optical densities at 280nm and correcting for human IgG. A 10% SDS-PAGE was used to test the purified IgG. Human sera were decomplemented by heating at 56°C for 30 min and dialyzed against normal solution before use.
Anti-GM1 ganglioside antibodies were not detected in the IgG preparations using a standard ELISA at IgG concentrations of 0.05 mg/ml (Prof. Angela Vincent, Department of Clinical Immunology, Oxford Radcliffe Hospital Trust, Oxford, UK).
Animals and muscle preparation
Animals were cared for in accordance with national guidelines for the human treatment of laboratory animals, which are comparable with those established by the National Institutes of Health. All efforts were made to minimize animal suffering and the number of animals used.
Experiments were performed on diaphragm, soleus, and levator auris muscle from male Swiss mice weighing 25-30 g. Mice were anesthetized with 2% tribromoethanol and exsanguinated, after which muscles were removed and dissected on a Sylgard-coated dish (Dow Corning, Midland, MI). Tissue was kept covered with a Ringer's normal solution (RN) [in mM: 137 NaCl, 5 KCl, 2 CaCl 2 , 1 MgSO 4 , 12 NaHCO 3 , 1 Na 2 HPO 4 , and 11 glucose (continuously bubbled with 95% O 2 -5% CO 2 )] and then transferred to a recording chamber to perform electrophysiological experiments at 25°C or was used for immunohistochemical analysis.
Electrophysiology
To evaluate spontaneous and evoked synaptic activity, miniature endplate potentials (MEPPs) and evoked endplate potentials (EEPs) were measured by intracellular recording. The electrophysiological equipments used have been described previously (Fratantoni et al., 2000) . Borosilicate glass capillaries were used for microelectrodes filled with 3 M KCl (20 -35 M⍀ resistance). Normal synaptic activity was confirmed in RN for all neuromuscular preparations used, after which IgG or drugs were evaluated. To perform the largest number of experiments with the IgG from each patient, we first found out the effective working concentration in each IgG sample (100 g to 400 g/ml). Because ALS-IgG incubating time was necessarily ϳ4 h, incubations were performed into a wet incubation chamber using RN so as to keep constant chamber humidity and consequently constant volume, viscosity, ion concentration, and pH of the incubation solution. Thus, all experiments shown here were made with 4 h incubation, except when stated. Control experiments were performed parallel to experiments in which IgG and/or drugs were used to evaluate synaptic activity, to rule out possible false-positive or false-negative results. Diaphragm muscles were removed, and, alternatively, the left or right hemidiaphragm was used to study the effects of ALS-IgG or Ctrl-IgG. All of the experiments performed with photosensitive drugs were performed avoiding direct illumination on the preparations. Goat IgG anti-human and goat IgG anti-rabbit were used for ALS-IgG or Ctrl-IgG immunoprecipitation (IP). Loading of BAPTA-AM was made in 0 mM Ca 2ϩ and 3 mM Mg 2ϩ for 30 min at 25°C, and for 30 min at 37°C, and then rinsing at 25°C in 0 Ca 2ϩ and RN. At least 30 synapses from three different animals were examined in each condition. Values are expressed as mean Ϯ SEM. Statistical significance was evaluated by a one-tailed Student's t test by comparing the mean synaptic activity with their own control in normal solution before any treatment with antibodies or drugs, except when stated.
Amplitudes of MEPPs at each synapse were normalized to Ϫ75 mV:
where A is the amplitude measured in millivolts, E r is the reversal potential [acetylcholine receptor (AChR) is assumed to be 0 mV], and E m is the mean membrane potential during the recording period. Interevent intervals measured were plotted and fitted to a one-order exponential and analyzed by 2 test (Origin 6.0; Microcal Software, Northampton, MA). All measurements on the recordings were performed using Clampfit 9.0 (Molecular Devices, Palo Alto, CA).
To evoke EPPs, the phrenic nerve was stimulated with two platinum electrodes coupled to a stimulus isolation unit (Grass Stimulator; Grass Instruments, Quincy, MA). -Conotoxin GIIIB at 1 M (Alomone Labs, Jerusalem, Israel) was used to prevent muscle contraction. Evoked neurotransmitter release was evaluated at a low [Ca 2ϩ ]/[Mg 2ϩ ] ratio, in which quantal content (QC) was estimated by the coefficient of variation. QC at 20 and 40 Hz was estimated after 6 s stimulation to avoid the initial facilitation and depression in a train of stimuli.
Paired-pulse facilitation (PPF) and posttetanic potentiation (PTP) were studied in the low [Ca 2ϩ ]/ [Mg 2ϩ ] solution (2 mM Ca 2ϩ /6.5 mM Mg 2ϩ ). PPF was evaluated by the change in EPP amplitude in the second EPP normalized to the first one. PTP was evaluated by comparing 10 stimuli at 0.5 Hz before and after a tetanic stimulation (500 stimuli at 100 Hz).
Tissue and immunohistochemistry
Immunohistochemistry on muscle cross sections. Diaphragm or soleus muscle were removed and fixed without delay for 3 min with 4% paraformaldehyde (PFA) in 0.1 M phosphate buffer, pH 7, at room temperature. Then, they were washed in phosphate buffer for 1 min, permeabilized in 1% Triton X-100 for 5 min, washed again in phosphate buffer for 1 min, and finally cryoprotected in 30% sucrose. All of the previous steps were done at 4°C, except when stated. Blocks of tissue were embedded in Tissue-Tek (OCT4583; Sakura, Tokyo, Japan), in a sealed plastic tube, and frozen. Cross sections, 40 m thick, were cut with a cryostat, and muscle sections were mounted onto gelatin-coated slides, air dried for 15 min, and stored at Ϫ20°C.
Muscle sections were processed simultaneously for double labeling by indirect immunofluorescence, and direct staining was performed with ␣-bungarotoxin coupled to tetramethylrhodamine (BgTx-R) (Invitrogen, Carlsbad, CA). Visualization of the human IgG was through a tagged IgG with FITC and of the anti-synaptotagmin antibody with a tagged IgG with Alexa Fluor 488 (Invitrogen). All incubations were performed at room temperature, using 10 mM PBS, pH 7.4, except when stated. Immunofluorescence experiments were performed according to Pagani et al. (2004) . In brief, sections were permeabilized with 0.1% Triton X-100, rinsed in PBS, and incubated with the primary antibody for 19 h at 4°C. Tissue was washed with PBS for 90 min. Sections were then incubated simultaneously with the secondary antibody and BgTx-R for 105 min and rinsed for 40 min in PBS. Finally, sections were mounted using ProLong Antifade (Invitrogen). To define the specific distribution patterns and autofluorescence level, control assays were performed with Ctrl-IgG as primary antibody or without primary antibody. No staining was observed in any control assay.
Immunohistochemistry on whole muscle fiber. Levator auris muscles were removed from the mice and carefully dissected, stretched, fixed with 1% PFA for 5 min, and rinsed in PBS. All of the procedures were done at 4°C using filtered solution through a 50 m pore size (Millipore). The primary antibody (200 g/ml ALS-IgG or Ctrl-IgG) was incubated overnight and washed for 20 min. The secondary FITC-labeled antibody (10 g/ml) and BgTx-R were incubated simultaneously for 2 h and rinsed for 1 h with PBS.
Microscopy and photography
A confocal microscope (BX61-FV300; Olympus Optical, Tokyo, Japan) equipped with an argon/helium-neon-G laser that allows simultaneous scanning was used to view and acquire the images of the immunofluorescent sections. Confocal images from cross-sectioned muscles were obtained with a PlanApo oil-immersion lens, 100ϫ objective, numerical aperture (NA) 1.4; those from whole-muscle fibers were obtained with a LUMplanFl water-immersion objective lens, 60ϫ, NA 0.9 (Olympus Optical). For experimental details, see Pagani et al. (2004) . Mean values of fluorescence signal for a particular antibody was obtained by optical density quantification after background subtraction from 12 synapses from three different animals using FluoView 300 (Olympus Optical). Laser alignment was tested by 4.2 m Tetra speck microsphere (Invitrogen).
Chemicals
Salts and all other reagents used were of analytical grade and purchased from Sigma (St. Louis, MO), except when stated. Tribromoethanol was purchased from Aldrich (Milwaukee, WI). Dihydropyridine was from Research Biochemicals (Natick, MA), and protease inhibitors were from Sigma (aprotinin, pepstatin A, and EGTA) or Calbiochem (San Diego, CA) (aprotinin and pepstatin A). BAPTA-AM and the synthetic polypeptide -conotoxin GVIA (GVIA) and -agatoxin IVA were from Alomone Labs.
Results
ALS-IgG triggers reversible synaptic potentiation of spontaneous transmitter release
ALS-IgG-mediated synaptic potentiation has been reported previously (Uchitel et al., 1988 (Uchitel et al., , 1992 . However, there are some uncertainties as to whether a component different from ALS-IgG may be responsible for the structural and functional modifications observed (Nyormoi, 1996) . Thus, to evaluate the effect of ALS-IgG on synaptic activity, MEPPs were recorded at neuromuscular junction (NMJ) before and after application of ALSIgG or control antibodies. Neither the Ctrl-IgG (15 of 15) nor 54.5% of the ALS-IgG (6 of 11) had an effect on MEPP frequency (Fig. 1 A) . However, ALS-IgG purified from the remaining five ALS patients increased synaptic activity after 4 h of incubation ( Fig. 1 A) . Synaptic activity was enhanced 2.5-to 3-fold compared with the control, without IgG or with control antibodies (Fig.  1 A, B) . Increment in synaptic activity correlated positively with incubation time, reaching a maximal rate of frequency of MEPP (759 Ϯ 211 per minute) after 9 h of incubation (Fig. 1C) . Positive ALS-IgG were used in the following experiments.
ALS-IgG-sp was independent of action potentials, because it was not affected by the presence of tetrodotoxin (0.5 g/ml) (Fig.  1 D) . To test whether the ALS-IgG effect could be attributable to a proteolytic action through a contaminant serine protease (Nyormoi, 1996) , we studied the effect of ALS-IgG on spontaneous synaptic activity by using ALS-IgG and muscles preincubated with protease inhibitors. The specific serine protease inhibitor (10 g/ml aprotinin) was not able to preclude the ALS-IgG-sp.
Moreover, the serine protease inhibitor alone did not introduce modifications at normal MEPP frequency. Furthermore, we studied aspartic and metalloprotease inhibition using pepstatin A (10 M) and EGTA (3 mM), respectively. Inhibition of these proteases did not prevent ALS-IgG-sp, even when said protease inhibitors were used all together (Fig. 1 D) . These results indicated that the synaptic potentiation was independent of protease activity (Fig. 1 D) .
After 6.5 h of incubation, ALS-IgG-sp was completely reversed by rinsing the nerve muscle preparation for 30 -45 min with normal solution (Fig. 1 D) , adding support to the idea that ALS-IgG-sp was not the result of an irreversible cellular damage, as could be expected from a contaminating proteolytic activity. This fast reversibility also indicated a weak interaction between the ALS antibodies and their antigenic target.
To further test the requirement of ALS-IgG to induce potentiation of spontaneous transmitter releases, we immunoprecipitated ALS-IgG or Ctrl-IgG using anti-human antibodies or antirabbit antibodies as control. The products of IP were used to evaluate their capability to modulate synaptic transmission. Incubation of the IP of ALS-IgG with anti-human antibodies did not alter transmitter release. In contrast, we observed synaptic potentiation in muscles incubated with the IP of ALS-IgG with anti-rabbit antibodies (Fig. 1 D) . As expected, Ctrl-IgG immunoprecipitated with anti-human antibodies had no effect on synaptic activity (Fig. 1 D) . These results showed that synaptic potentiation is ALS-IgG dependent.
To characterize ALS-IgG-sp, we studied whether ALS-IgG changes the properties of spontaneous synaptic activity. We examined MEPP frequency distribution, mean amplitude of MEPPs, and interval time distribution between MEPPs. MEPP frequency distribution was more spread out after ALS-IgG incubation ( p Ͻ 0.05) (Fig. 2 A, B) . However, we did not find significant differences in interval time distribution or in the mean amplitude of MEPPs recorded from ALS and control treated muscles ( p Ͼ 0.05) ( Fig. 2 A-F ). We rarely observed giant postsynaptic potentials. Absence of changes in mean amplitude of MEPPs after ALS-IgG application indicated that quantal size was not affected by ALS-IgG ( Fig. 2 E, F ).
ALS-IgG did not affect action potential-evoked synaptic transmission
Although antibodies from ALS patients affect spontaneous synaptic transmission and Ca 2ϩ current (Uchitel et al., 1988; Delbono et al., 1991) , very little is known about the effect of ALS-IgG on action potential-evoked synaptic transmission. O'Shaughnessy et al. (1998) observed an increment in QC mediated by ALS-IgG at low frequency of electrical stimulation. However, studying anconeus muscles from ALS patients, Maselli et al. (1993) detected a reduction in QC with respect to control patients.
Despite the fact that ALS-IgG-sp was independent of action potential ( Fig. 1 D) , ALS-IgG can possibly affect mechanisms common to spontaneous and evoked synaptic transmission (i.e., a particular type of calcium signal). Thus, we investigated the effect of ALS-IgG on EPPs evoked by nerve stimulation at physiological frequencies of 20 and 40 Hz (Norris and Gasteiger, 1955) . We examined the effect of ALS-IgG, which enhanced spontaneous neurotransmission, in which each antibody was studied on at least 30 synapses from three diaphragm muscles. ALS-IgG application did not modify QC of transmitter release.
The QC values measured at 20 and 40 Hz were similar to those obtained from neuromuscular preparations incubated with h-Ctrl-IgG, d-Ctrl-IgG, or without IgG. Mean QC from control and ALS at 20 Hz was 21.88 Ϯ 1.61 and 17.83 Ϯ 1.53 and at 40 Hz was 20.57 Ϯ 1.73 and 22.04 Ϯ 2.05, respectively ( p Ͼ 0.05).
To determine whether ALS-IgG affects short-term synaptic plasticity, we studied the effect of ALS-IgG on PPF and PTP. ALS-IgG modified neither PPF nor PTP compared with Ctrl-IgG or solution without IgG (data not shown). The values recorded for PPF with an interpulse time of 10, 25, and 50 ms were as follows: for ALS-IgG, 1.16 Ϯ 0.04, 1.07 Ϯ 0.03, and 1.19 Ϯ 0.06; and for Ctrl-IgG, 1.03 Ϯ 0.05, 1.09 Ϯ 0.01, and 1.07 Ϯ 0.04 ( p Ͼ 0.05). PTP values showed a range from 105.1 to 131.9% for ALS and from 107.2 to 141.4% for control antibodies. Thus, these results suggested that ALS-IgG did not affect action potentialdependent synaptic transmission.
ALS-IgG enhances asynchronous and delayed release at 20 and 40 Hz stimulation
A coordinate fusion of several synaptic vesicles triggers an evoked EPP (synchronous release), and a noncoordinate fusion produces MEPP-like events (asynchronous release). Alterations in synaptic components involved in neurotransmission (i.e., release machinery and Ca 2ϩ homeostasis) could modify the synchronic- The sodium channel blocker TTX (0.5 g/ml) did not prevent ALS-IgG potentiation(TTXϩALS-IgG).NotethatlabelsinwhichthedrugnameprecedesIgGmeanthatthedrug was present before ALS-IgG-sp had developed, whereas labels in which IgG precedes the drug name indicate that the drug was applied after the ALS-IgG-sp had developed. However, ALS-IgG effect was removed by washing with normal solution after 6.5 h of incubation (ALS-IgG/Wash 6.5) or was prevented by immunoprecipitation of the ALS-IgG with IgG-anti-human (ALS-IgG/Hu) but not with IgGanti-rabbit (ALS-IgG/Rb). Also, synaptic activity was not modified when we used Ctrl-IgG immunoprecipitatedwithIgG-anti-human(Ctrl-IgG/Hu).Preincubationwithaprotinin(10g/ml),pepstatin A (10 M), and EGTA (3 mM) did not prevent ALS-IgG effect (ALS-IgG/Inh ity of synaptic vesicle fusion increasing asynchronous release (Mochida et al., 1996; David and Barrett, 2003) . Because ALS-IgG seems to affect Ca 2ϩ homeostasis, we studied its effect on the asynchronous release that occurs both during and after nerve stimulation (delayed release).
We observed that a 30 s train of electrical stimulation at 20 and 40 Hz induced an asynchronous release of 211 Ϯ 45 and 146 Ϯ 49 MEPPs/min, respectively, in muscles incubated for 4 h with control antibody (h-Ctrl-IgG and d-Ctrl-IgG) (Fig. 3 A, B) . These observations showed a negative correlation between stimulation frequency and asynchronous release (r ϭ Ϫ0.39) ( p Ͻ 0.01) (Fig.  3D ). Studies at neuromuscular and hippocampal synapses have shown that an increase in the asynchronous release reduces the synchronous release, probably because of the fact that vesicles involved in synchronous and asynchronous release derive from the same source (David and Barrett, 2003; Otsu and Murphy, 2004) (also see Sara et al., 2005) .
ALS-IgG-treated muscles stimulated at 20 and 40 Hz showed a much higher frequency of asynchronous release (344 Ϯ 48 and 1028 Ϯ 252 MEPPs/min, respectively) and inverted the correlation between the stimulation frequency and asynchronous release (r ϭ 0.87) ( p Ͻ 0.01) (Fig. 3 B, D) . The increment in asynchronous release was time dependent and detectable ϳ5 s after the stimulation train started (Fig. 3B) . Interestingly, the increment in asynchronous neurotransmission did not reduce synchronous release at any frequency of stimulation studied (QC at 20 and 40 Hz), as could be expected from previous studies (David and Barrett, 2003; Otsu and Murphy, 2004) .
ALS-IgG also increased delayed MEPP-like events after a train of action potentials (30 s at 20 or 40 Hz). The delayed events in Ctrl-IgG began to return to normal rate after 1-1.5 min, whereas the delayed events in ALS-IgG remained higher (Fig. 3D) . Thus, during and after a train of action potentials (30 s at 20 or 40 Hz), ALS-IgG promoted asynchronous and delayed release. The ALSIgG effect on asynchronous and spontaneous release, but not on synchronous release, could be because the ALS-IgG affects mechanisms associated with those modes of transmitter release (i.e., intracellular calcium stores) (Narita et al., 2000; David and Barrett, 2003; Otsu and Murphy, 2004 ) that involve a different type of synaptic vesicles pool (Sara et al., 2005) and distinct release machinery (Hua et al., 1998) . Furthermore, at mouse NMJ, a cross talk between synchronous and asynchronous release is apparent only when asynchronous release reaches ϳ1000 quanta/s (David and Barrett, 2003) , a higher rate than that induced by ALS-IgG (ϳ1000 quanta/min). Thus, considering the huge size of the synaptic vesicle pool at the MNT and the small number of quanta released asynchronously, ALS-IgG would not be expected to influence the availability of synaptic vesicles for synchronous release in our experiments.
Immunostaining reveals a presynaptic localization of the ALS-IgG molecular target at rodent NMJ Our previous experiments strongly suggest that ALS-IgG interacts with a molecular component from the neuromuscular preparation and mediates synaptic potentiation. In fact, it has been suggested that ALS-IgG may be interacting with calcium channels, including non-neuronal VDCCs from skeletal muscle (Ca v1.1 , ␣1 S subunits), thereby altering calcium currents (Delbono et al., 1991; Smith et al., 1992) . Furthermore, an interaction has been suggested with the receptor type ␥ for the Fc segment of antibodies (Fc␥R) (Mohamed et al., 2002) . To examine whether ALS-IgG presents immunoreactivity against a molecular target and, if so, where it is located, we studied the binding of ALS-IgG to permeabilized muscle sections and whole nonpermeabilized muscle fibers by immunohistochemistry and confocal microscopy.
ALS-IgG, Ctrl-IgG, or anti-synaptotagmin antibodies were used for indirect immunofluorescence experiments. Double labeling was made by indirect immunostaining (Fig. 4 Ad-Af ) combined with a direct staining using ␣-bungarotoxin to detect postsynaptic AChRs (Fig. 4 Aa-Ac) on mouse diaphragm and soleus muscle cross sections.
We studied the immunoreactivity of 13 ALS-IgG and 15 CtrlIgG. We observed that ALS-IgG from 6 of 13 patients (46.15%) rendered positive labeling, with similar localization at the NMJ. In one case (1 of 13), we observed slight positive staining at NMJ. Furthermore, ALS-IgG from another patient (1 of 13) showed negative staining at NMJ but positive staining in axons. (1-4) . A particular antibody was studied on three synapses from three animals. Each bar represents the mean value and SEM obtained from 12 synapses from 12 animals to ALS antibodies and 18 synapses from 18 animals to control antibodies. Note that asynchronous release was higher at 20 Hz than at 40 Hz in Ctrl-IgG, whereas in ALS-IgG, it was much higher at 40 Hz than at 20 Hz. *p Ͻ 0.05.
The remaining ALS-IgG (5 of 13) did not show immunoreactivity at NMJ, axons, or muscle fibers. All Ctrl-IgG (15 of 15) showed negative immunoreactivity against neuromuscular preparations.
Staining revealed a precise labeling at synapses when ALS-IgG was used as primary antibody (Fig. 4 Ab,Ae) but not when different Ctrl-IgG were used (Fig. 4 Aa,Ad). Moreover, we observed an exact colocalization of AChRs with the ALS-IgG molecular target and the presynaptic marker synaptotagmin in optic sections of 2 m (data not shown). It is interesting to note that there is no labeling of muscle fibers, suggesting that, at least on fixed muscles, ALS-IgG does not interact with VDCC ␣1 S subunits localized at the muscle fibers. We observed similar results on cross sections of mouse and rat diaphragm and on soleus muscle (data not shown).
With the aim of determining whether the molecular target for ALS-IgG was located at nerve terminal or at another NMJ component, such as Schwann cell or muscle fibers, we studied positive ALS-IgG immunoreactivity on cross sections of mouse denervated soleus muscle. Double staining on denervated muscles showed positive labeling at NMJ for AChRs (Fig. 4 Ac) but not for ALS-IgG (Fig. 4 Af ) or synaptotagmin (data not shown), indicating that the molecular component recognized by ALS-IgG is at MNT (Fig. 4 Ac,Af ). The negative labeling for synaptotagmin confirmed effective denervation.
To further investigate whether antibody binding site is located on the nerve terminal surface, we performed immunostaining experiments on whole nonpermeabilized muscle fibers (Fig. 4 B) using three of the ALS-IgG that had shown positive immunoreactivity in muscle cross sections (Fig. 4 A) . ALS-IgG showed a positive stain colocalizing with the postsynaptic receptors (Fig.  4 Bd,Be), whereas control antibodies did not show specific staining (Fig. 4 Ba,Bc). These results strongly indicated that ALS-IgG interacts with a molecule located at the surface of the motor nerve terminals and in turn triggers synaptic modulation.
Correlation between ALS-IgG immunoreactivity and synaptic potentiation mediated by ALS-IgG in neuromuscular synapses
We have shown that ALS-IgG from ϳ50% of ALS patients induce synaptic potentiation and positive immunostaining, whereas Ctrl-IgG showed neither synaptic potentiation nor immunoreactivity against MNT. To examine whether synaptic potentiation and positive staining were independent events, we analyzed the correlation between synaptic potentiation and immunostaining in eight different ALS antibodies. None of the ALS-IgG with negative labeling at NMJ modulated synaptic transmission, whereas all ALS-IgG with positive immunoreactivity did. Figure 5 shows mean values of ALS-IgG-sp and immunolabeling of the ALS-IgG studied. Using values of fluorescence signal (independent variable) against mean synaptic activity (dependent variable) from all IgG studied, we estimated the correlation coefficient (r ϭ 0.96) and the coefficient of determination (r 2 ϭ 0.92) ( p Ͻ 0.01). This correlation suggested that ALS-IgG-sp is the consequence of ALS-IgG immunoreactivity against MNT. Thus, considering both immunoreactivity and synaptic potentiation studies, we were able to distinguish two different populations of ALS patients. The first contained IgG immunoreactive against MNT and the ability to modulate synaptic transmission, whereas the second did not show any of these features. We will call these two groups "immune-associated ALS" and "idiopathic ALS," respectively. Although there was not a common clinical examination protocol to evaluate the disease progression in each patient, it was possible to determine that there were no clear differences between ALS patients with reacting and nonreacting IgG regarding age at onset (53 vs 62 years old), sex (three males/two females vs four males/ two females), patients with bulbar onset (33 vs 25%), patients with limb onset (67 vs 75%), time to gastrostomy (22 vs 26 months), and time to death or tracheotomy (45 vs 50 months), respectively.
The lack of immunoreactivity by IgG and synaptic potentiation activity in familial ALS
To evaluate whether immunoreactivity was a consequence of the disease, we examined whether IgG purified from three familial ALS patients (fALS-IgG) showed any immunoreactivity and whether they were capable of modulating spontaneous transmitter release at neuromuscular synapses. We observed that, in diaphragm muscles, fALS-IgG showed no ability to modulate spontaneous synaptic activity, even at an extremely high IgG concentration (6 mg/ml) and after a prolonged incubation time (7 h). Furthermore, immunostaining revealed the absence of the immunoreactivity of fALS-IgG against NMJ, axons, or muscle fibers in mouse diaphragm and soleus muscles.
Mechanisms underlying ALS-IgG synaptic modulation
We have shown that ALS-IgG strongly modified the spontaneous frequency of MEPPs in the absence of stimulation, as well as the frequency of asynchronous events during and after stimulation. However, the mechanism underlying this phenomenon needs to be understood. Thus, we concentrated our efforts on studying the signaling pathway responsible for neurotransmitter spontaneous release potentiation induced by four ALS-IgG with positive immunostaining (antibodies from patients 1-4).
Participation of the complement
Antibodies from Guillain-Barre patients may interact with antigens at MNT and trigger activation of complement (Cp), which produces a high neurotransmitter release rate (Bullens et al., 2002) . To evaluate the participation of complement in ALS-IgGsp, we tested whether the addition of Cp boosts ALS-IgG-sp in two experimental conditions: (1) adding Cp at the time in which ALS-IgG-sp was expected to be apparent, and (2) after ALSIgG-sp was observed. We used normal human sera as a source of Cp and sera with inactivated complement as a control, as by Bullens et al. (2002) . Cp application under conditions 1 and 2 did not boost ALS-IgG-sp. On the contrary, serum with or without Cp induced an MEPP frequency reduction (data not shown). Furthermore, ALS-IgG treated with the standard procedure for complement inactivation was still capable of inducing synaptic potentiation (RN, 1 Ϯ 0.09; ALS-IgG, 2.7 Ϯ 0.15) ( p Ͻ 0.05). We tested four ALS-IgG with positive immunostaining, in which each antibody was studied at least on 30 synapses from three animals. These results did not support the hypothesis that ALSIgG-sp is a complement-mediated phenomenon.
ALS-IgG-induced synaptic potentiation requires an initial Ca
2؉ influx through a Ca v 2.2 calcium channel At adult neuromuscular junction, P/Q VDCC mediates transmitter release (Katz et al., 1997) . However, other types of VDCCs are also present at NMJ (Pagani et al., 2004) . To further investigate the mechanisms underlying ALS-IgG-sp, we examined whether the ALS-IgG effect requires Ca 2ϩ influx by using specific blockers to P/Q-, L-, and N-type VDCCs.
L-type or P/Q-type VDCC blockers (10 mM nitrendipine or 100 nM -agatoxin IVA, respectively) did not prevent ALS-IgG effect when they were used either alone or jointly (Fig. 6 A) . In contrast, the N-type VDCC blocker GVIA (1 M) completely prevented the ALS-IgG effect (Fig. 6 A) . Additionally, the permeable Ca 2ϩ chelator BAPTA-AM (10 M) prevented ALS-IgG-sp (Fig. 6 A) . To evaluate whether the ALS-IgG-sp requires a continuous Ca 2ϩ influx through N-type VDCCs (Ca v2.2 ), we blocked Ca v 2.2 channels after the ALS-IgG effect was established. Surprisingly, the Ca v 2.2 VDCC blocker GVIA (1 M) was not able to reverse the ALS-IgG effect (Fig. 6 B, Table 1 ). Although GVIA blocks Ca v 2.2 channels by pore occlusion and does so almost irreversibly (Doughty et al., 1998) , these results could be explained by a competitive interaction between the toxin and ALSIgG. Thus, we examined this hypothesis by using GVIA at high concentration (3 M), but GVIA neither interrupted ALS-IgG-sp nor prevented the increment in synaptic activity dependent on incubation time (Fig. 1C) . A second possibility examined was that ALS-IgG might induce a conformational change over Ca v 2.2 channels, blocking the interaction between the toxin and the Ca v 2.2 channels. Likewise, the interaction between the toxin and the channel would not allow that of the ALS-IgG with its molecular target, and both would be mutually excluded. To examine this hypothesis, we proceeded to treat three mouse diaphragm muscles with GVIA or vehicle and, thereafter, fixed and processed muscles for immunohistochemistry. Pretreatment with GVIA did not preclude immunostaining when ALS-IgG were used as primary antibody, given the same labeling on the treated and nontreated muscles (data not shown). In addition, we tested that a mix of Co 2ϩ (300 M) and Ni 2ϩ (300 M) is effective to block VDCCs and reverse MEPP frequency increment induced by 10 mM K ϩ . However, Co 2ϩ /Ni 2ϩ application was ineffective to reverse the ALS-IgG effect (Fig. 6C) . These experiments with the Ca v 2.2 channel blocker denote the absence of competitive and noncompetitive interaction between GVIA and ALS-IgG. Jointly, these molecular and physiological studies revealed that ALS-IgG did not interact with Ca v 2.2 channels and that ALS-IgG-sp requires an initial influx of Ca 2ϩ through Ca v 2.2, channels but not a constitutive Ca 2ϩ influx. Additionally, these findings showed that the Ca 2ϩ signal from Ca v 2.2 channels might somehow regulate neurotransmitter release at mouse neuromuscular synapses (Protti et al., 1991) .
The ALS-IgG effect requires activation of phospholipase C and involves continuous and simultaneous participation of 1,4,5-trisphosphate and ryanodine-sensitive receptors Our previous findings suggested that the ALS-IgG effect requires not only Ca 2ϩ influx through Ca v 2.2 channels but also a concomitant activation of signaling pathways when the ALS-IgG-sp became independent of Ca 2ϩ influx. Thus, activation of some pathways may explain the high spontaneous transmitter release independent of Ca 2ϩ influx through Ca v 2.2 (Fig. 6 ). To examine this hypothesis, we tested several pathways that may be involved in the ALS-IgG potentiation phenomenon. The best characterized signaling pathways, which may lead to synaptic potentiation, are those that involve intracellular Ca 2ϩ mobilization and also pathways that involve VDCC activation. Intracellular Ca 2ϩ mobilization could take place through 1,4,5-trisphosphate receptors (IP 3 Rs) and ryanodine receptors (RyRs), and VDCC activation could take place through protein kinase C (PKC) or cAMP-dependent protein kinase (PKA) (Berridge et al., 2003) . Because IP 3 R and PKC may be under the control of phospholipase C (PLC), we began studying whether the inhibition of PLC by U73122 (1-[6[[(17␤)-3-methoxyestra-1,3,5(10)-trien-17-yl] amino]hexyl]-1 H-pyrrole-2,5-dione) (10 M), a specific PLC inhibitor, affected ALS-IgG-sp. Inhibition of PLC prevented but did not interrupt the ALS-IgG effect (Fig. 7A) . We also observed that orthovanadate (20 M), a specific tyrosine phosphatases inhibitor, may induce an ALS-IgG-sp-like effect with similar magnitude and time course. The ability of the orthovanadate to mimic ALS-IgG-sp is consistent with the recruitment of tyrosine phosphorylation necessary for PLC activation in ALS-IgG-sp.
Activated PLC can hydrolyze phosphatidylinositol 4,5-bisphosphate, generating the second messengers diacylglycerol (DAG) and IP 3 . Both DAG and IP 3 in the presence of Ca 2ϩ can activate PKC and IP 3 R, respectively, leading to a [Ca 2ϩ ] i incre- ment (Berridge et al., 2003) . To define the PKC or IP 3 R contribution, we evaluated the effect of inhibiting these pathways. Inhibition of PKC using H7 [1-(5-isoquinolinesulfonyl)-2-methylpiperazine dihydrochloride] (100 M), a specific serine/ threonine inhibitor, did not prevent the ALS-IgG-sp effect (Fig.  7A) , whereas APB, an IP 3 R antagonist, did (Fig. 7A) . However, IP 3 R antagonist did not reverse the ALS-IgG effect when the potentiation has already developed.
To examine the involvement of RyR (O'Shaughnessy et al., 1998) in ALS-IgG-sp, we used ryanodine at a high concentration (20 M) as antagonist for RyR. We observed absolute prevention of ALS-IgG-sp (Fig. 7A) . Again, once ALS-IgG-sp had developed, ryanodine application did not reverse synaptic activity to basal level (Fig. 7A) . However, the magnitude of ALS-IgG-sp after ryanodine application (2.29 Ϯ 0.08 MEPPs/min) compared with ALS-IgG-sp without ryanodine (3.95 Ϯ 0.42 MEPPs/min) suggested that ryanodine prevented full synaptic potentiation. Nevertheless, using both RyR and IP 3 R antagonists together, we observed a reversal of ALS-IgG-sp. Regardless of the ALS-IgG used (from any patient), reversal of synaptic activity was complete in 41.7% of the experiments (5 of 12), showing a 92.5% mean reversal. The magnitude of the reversal showed a negative correlation with the magnitude of ALS-IgG-sp reached (Fig. 7B , Table  1 ). ALS-IgG-induced Ca 2ϩ release from intracellular Ca 2ϩ stores would be consistent with an increase of spontaneous and asynchronous release but not an alteration in synchronous release because (1) enhancement of spontaneous and asynchronous release is feasible by Ca 2ϩ release through RyR (Narita et al., 2000; Angleson and Betz, 2001) , and (2) in association with an increased asynchronous release, QC is only depressed when asynchronous release is massive (ϳ1000 quanta/s) (David and Barrett, 2003) or when the stimulation at high frequency is longer than 2 min (Narita et al., 2000) .
Prevention of ALS-IgG effect by inhibition of RyR or IP 3 R indicated that these receptors were necessary to activate an increment in transmitter release in both MEPP frequency (Fig. 7A ) and asynchronous release (data not shown). Moreover, the requirement of inhibition of both receptors to reverse the synaptic potentiation indicated that both RyR and IP 3 R contributed to its maintenance.
Together with activation of PLC, the phosphoinositide 3-kinase (PI3-K) pathway may also be activated (Robidoux et al., 1998) and may regulate synaptic potentiation (Yang et al., 2001 ) and neurotransmitter release by production of inositol 3,4,5-trisphosphate (Schiavo et al., 1996) . We examined the participation of PI3-K in ALS-IgG potentiation by using specific PI3-K inhibitors. Application of neither wortmannin (1 M) (Fig. 7A ) nor LY294002 [2-(4-morpholinyl)-8-phenyl-1(4H)-benzopyran-4-one] (5 M) had any effect on ALS-IgG-sp. In fact, LY294002 increased the synaptic activity by itself (data not shown), which is consistent with previous observations (Rizzoli and Betz, 2002) . Furthermore, because ALSIgG-sp required a long incubation time, we examined whether protein synthesis was required during the incubation. The protein synthesis inhibitor cycloheximide (10 g/ml) did not alter ALS-IgG-sp (Fig. 7A) .
Our pharmacological results suggested that ALS-IgG-sp was dependent on [Ca 2ϩ ] i , which can be inferred from MEPPs by using an appropriate Hill coefficient and half-saturation value (K d ) (Angleson and Betz, 2001 increment in MNT. This approach showed that, after 4 and 8 h of incubation, ALS-IgG increased [Ca 2ϩ ] i to ϳ200 nM and 8 M, respectively.
Additionally, these results provide physiological evidence for a functional coupling between N-type VDCC, PLC, IP 3 R, and RyR in neuromuscular synapses. We confirmed these results by using antibodies purified from four ALS patients with positive immunostaining. Results from the most relevant experiments are summarized in Table 1 .
Discussion
Significance of autoantibodies in ALS
We have shown that IgG from a group of ALS patients binds to MNT, resulting in potentiation of spontaneous and asynchronous release. Several pieces of evidence supported this conclusion. First, protease inhibitors did not preclude ALS-IgG-sp (Fig.  1 D) (Nyormoi, 1996) . Second, immunoprecipitation using antihuman, but not anti-rabbit, antibodies prevented ALS-IgG-sp (Fig. 1 D) . Third, these results were consistent with the purity of the purified IgG tested by SDS-PAGE. Fourth, ALS-IgG effect is unlikely to be the result of nerve terminal degeneration because it was reversed after as long as 6.5 h exposure (Figs. 1 D, 7B) . Fifth, ALS-IgG interacts with an antigen present in the external surface of the MNT (Fig. 4) . Sixth, a high correlation supported that ALS-IgG-sp was a consequence of immunoreactivity (Fig. 5) .
The lack of effect of pepstatin A (a protease inhibitor and also a potent inhibitor of Fc␥R) (Athanassakis et al., 2000) on ALSIgG-sp is in disagreement with the proposed interaction between ALS-IgG and Fc␥R (Mohamed et al., 2002) . Furthermore, if ALSIgG-sp were the consequence of an interaction between ALS-IgG and Fc␥R, we should have observed positive labeling with all of the IgG tested, including Ctrl-IgG (Ober et al., 2001) . Moreover, no reactivity was observed with any of the IgG used at vascular endothelium, in which Fc␥R is highly enriched (Medesan et al., 1998) . Immunostaining observed with ALS-IgG therefore indicates that the Fab segment mediated the antigen-antibody interaction.
Presence of autoantibodies in sera of ALS patients has been thought to be a consequence of the disease (Drachman, 2000) . Here, we presented evidence to the contrary. The hypothesis predicts that the antibodies generated in ALS patients would be immunoreactive against a wide variety of molecules. We, however, detected immunoreactivity against specific neuronal components with specific localization (Fig. 4) . Also, although patients with fALS showed virtually the same clinical and degenerative features as sporadic ALS patients, the IgG purified from fALS patients, as well as ϳ50% of the ALS-IgG, showed no immunoreactivity and did not induce synaptic potentiation (Fig. 1 A) .
Hence, consistent with the notion that ALS is a syndrome, our results revealed that, in ϳ50% of ALS patients, MNTs constitute a target for autoimmune response (Vincent, 1999) , whereas in the remaining ALS patients, different mechanisms may be involved (Figs. 1 A, 5) . Thus, staining assays can be instrumental to distinguishing two groups of ALS patients, which must be considered differently in future studies and therapeutic approaches.
Signaling pathways regulating ALS-IgG-induced synaptic potentiation
Controversial evidence has been presented about an interaction between ALS-IgG and VDCCs (Ordonez and Sotelo, 1989; Kimura et al., 1994; R. G. Smith et al., 1994; Arsac et al., 1996) and their capability to modify Ca 2ϩ currents. However, the effect of ALS-IgG on Ca 2ϩ currents seems to be dependent on the cellular type studied. For example, a decrease of Ca 2ϩ currents has been
